Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Conmed (CNMD) EBITDA Margin (2016 - 2026)

Conmed filings provide 17 years of EBITDA Margin readings, the most recent being 4.87% for Q1 2026.

  • On a quarterly basis, EBITDA Margin rose 253.0% to 4.87% in Q1 2026 year-over-year; TTM through Mar 2026 was 4.93%, a 352.0% decrease, with the full-year FY2025 number at 4.34%, down 513.0% from a year prior.
  • EBITDA Margin hit 4.87% in Q1 2026 for Conmed, down from 5.27% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 15.68% in Q3 2022 to a low of 62.28% in Q2 2022.
  • Median EBITDA Margin over the past 5 years was 6.43% (2024), compared with a mean of 3.2%.
  • Biggest five-year swings in EBITDA Margin: crashed -6923bps in 2022 and later surged 6724bps in 2023.
  • Conmed's EBITDA Margin stood at 11.5% in 2022, then dropped by -2bps to 11.27% in 2023, then fell by -24bps to 8.56% in 2024, then tumbled by -38bps to 5.27% in 2025, then decreased by -8bps to 4.87% in 2026.
  • The last three reported values for EBITDA Margin were 4.87% (Q1 2026), 5.27% (Q4 2025), and 1.95% (Q3 2025) per Business Quant data.